Also known as: Haisco
Haisco Pharmaceutical Group is a Chinese pharmaceutical company engaged in R&D, manufacturing, and commercialization of medicines across multiple therapeutic areas.
China’s cross-border biotech outlicensing hit US$60 billion in the first quarter of 2026. AbbVie’s up to $745 million Haisco pain deal highlights multinationals’ rising interest in Chinese drug assets.
Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.
